Akèy › Kansè fwa (Kasinòm epatoselilè) › Kalifòni › Los Angeles
Etid klinik pou Kansè fwa (Kasinòm epatoselilè) nan Los Angeles, CA
19 etid pou Kansè fwa (Kasinòm epatoselilè) ap chèche patisipan nan sit nan ak bò kote Los Angeles (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Ap rekriteFaz 1/2
- START Los Angeles, LLC, Los Angeles
- Keck Hospital of USC, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- ak 3 plis
National Liver Cancer Screening Trial
Ap rekriteFaz 4
- University of Southern California, Los Angeles
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Ap rekriteFaz 1/2
- Local Institution - 0070, Los Angeles
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Ap rekriteFaz 1
- USC Norris Comprehensive Cancer Center, Los Angeles
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
Ap rekriteFaz 2
- USC Norris Comprehensive Cancer Center, Los Angeles
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Ap rekriteEtid obsèvasyon
- Cedars-Sinai Medical Center, Los Angeles
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Ap rekriteFaz 3
- Research Site, Los Angeles
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Ap rekriteFaz 1
- University of Southern California, Los Angeles
- Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer, Los Angeles
- Cedars-Sanai Medical Center, Los Angeles
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ap rekriteFaz 1/2
- Children's Hospital Los Angeles, Los Angeles
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- University of California, Los Angeles (UCLA), Los Angeles
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
Ap rekriteFaz 1/2
- Research Site, Los Angeles
A Study of MGC026 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- The Angeles Clinic and Research Institute, Los Angeles
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Ap rekriteFaz 1/2
- Los Angeles Cancer Network, Los Angeles
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Ap rekriteFaz 1/2
- Children's Hospital Los Angeles, Los Angeles
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Ap rekriteFaz 1
- Clinical Trial Site, Los Angeles
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 2
- USA06-0, Los Angeles
- USA16-0, Los Angeles
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Ap rekriteFaz 1/2
- Norris Comprehensive Cancer Center, Los Angeles
Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots
Ap rekriteEtid obsèvasyon
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site 125, Los Angeles
- Research Site 133, Los Angeles
- Research Site 103, Los Angeles
Etid Kansè fwa (Kasinòm epatoselilè) nan lòt vil
- Houston, TX31 etid
- New York City, NY24 etid
- Dallas, TX19 etid
- Boston, MA18 etid
- Cleveland, OH18 etid
- Philadelphia, PA16 etid
- Chicago, IL16 etid
- Pittsburgh, PA15 etid
- San Francisco, CA14 etid
- Orange, CA14 etid
- Jacksonville, FL14 etid
- San Antonio, TX13 etid
Lòt etid nan Los Angeles
- Kansè Poumon ki pa ti selil87 etid
- Kansè (tout kalite)74 etid
- Kansè nan tete73 etid
- Kansè pwostat61 etid
- Kansè kolorektal59 etid
- Kansè Metastatik57 etid
- Kansè ovè50 etid
- Kansè poumon45 etid
- Karsinòm selil skuamèz tèt ak kou42 etid
- Kansè pankreyas35 etid
- Kansè Endomèt34 etid
- Melanom34 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.